Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a "top-Down" approach to intestinal fibrosis in mice

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 460-471

  Johnson, Laura A ^a   Luke, Amy ^a   Sauder, Kay ^a   Moons, David S ^a   Horowitz, Jeffrey C ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

colitis; Crohn's disease; intestinal fibrosis; Salmonella typhimurium; top down interventional approach

Indexed keywords

LEVOFLOXACIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; ENTERITIS; ERADICATION THERAPY; FEMALE; FIBROGENESIS; GENE EXPRESSION; HISTOPATHOLOGY; INTESTINAL FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; SALMONELLA TYPHIMURIUM INFECTION; SALMONELLOSIS; TH1 CELL;

ACTINS; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFECTIVE AGENTS; CECUM; COLITIS; COLON; CYTOKINES; FEMALE; FIBROSIS; MICE; MICE, INBRED CBA; OFLOXACIN; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; TIME FACTORS;

EID: 84857361715     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21812     Document Type: Article

References (20)

1. Andres PG, Friedman LS,. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999; 28: 255-281, vii. (Pubitemid 29306479)
2. Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003; 98: 2712-2718. (Pubitemid 38020113)
3. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250. (Pubitemid 34784976)
4. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000; 95: 1955-1960.
5. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006; 101: 1030-1038. (Pubitemid 43725317)
6. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777-782. (Pubitemid 33096034)
7. Grassl GA, Valdez Y, Bergstrom KS, et al. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology. 2008; 134: 768-780.
8. Brand S,. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152-1167.
9. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2: 541-546. (Pubitemid 47040018)
10. Higgins PD, Johnson LA, Sauder K, et al. Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice. Comp Immunol Microbiol Infect Dis. 2011; 34: 247-257.
11. Strober W, Zhang F, Kitani A, et al. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol. 2010; 26: 310-317.
12. Cosnes J,. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig Dis. 2009; 27: 516-521.
13. Jones DW, Finlayson SR,. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010; 252: 307-312.
14. Peyrin-Biroulet L, Lemann M,. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33: 870-879.
15. Vermeire S, van Assche G, Rutgeerts P,. Review article: Altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther. 2007; 25: 3-12. (Pubitemid 44902859)
16. Hanauer SB,. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27: 536-541.
17. Domenech E, Manosa M, Cabre E,. Top-down therapy: is the evidence strong enough? Dig Dis. 2009; 27: 306-311.
18. Lin MV, Blonski W, Lichtenstein GR,. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010; 4: 167-180.
19. Selman M, King TE, Pardo A,. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134: 136-151. (Pubitemid 32096342)
20. Rieder F, Lawrance IC, Leite A, et al. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis. 2011 [Epub ahead of print].